Pulmonary Edema and Respiratory Failure DRG Reimbursement

Summary & Overview

Pulmonary Edema and Respiratory Failure: Inpatient Reimbursement Overview

DRG 189 addresses inpatient episodes for pulmonary edema and respiratory failure, conditions that frequently require advanced respiratory support and intensive care resources. Proper classification in this Diagnosis-Related Group is important for Medicare inpatient reimbursement because it influences payment weightings, resource allocation, and hospital case mix.

Pulmonary Edema and Respiratory FailureDRG Pulmonary Edema and Respiratory FailureDRG 189Diagnosis-Related GroupInpatient ReimbursementMedicarePulmonologyCritical CareMechanical VentilationHospital Coding

DRG 189 Overview

DRG 189 covers inpatient admissions for pulmonary edema and respiratory failure, including cases requiring varying levels of ventilatory support and oxygenation management. This Diagnosis-Related Group captures high-acuity respiratory conditions that often drive longer lengths of stay, intensive resource utilization, and higher costs. For Medicare payment, classification into DRG 189 affects base reimbursement and adjustments related to comorbidities, procedures, and discharge disposition. Accurate clinical documentation and coding are essential because they determine case mix and payment under the Medicare inpatient prospective payment system.

National Payment Rates

Across commercial payers the reimbursement range for DRG 189 spans from about $370 to $46K, with notable payer medians from $12K (BCBS) up to $22K–$20K for Aetna and Anthem respectively; the widest spread is roughly $46K between the lowest and highest reported values. See the table and chart below for payer-level percentiles and distributions. Blue Cross Blue Shield, Anthem, Cigna, and Aetna are shown individually.

Mean Rates by Payer — National — DRG 189

The CMS 2023 data represent national Medicare fee-for-service inpatient payments reported under the CMS Provider Utilization and Payment Data program. The table below shows average total payment ($11.5k), average submitted covered charges ($54.0k), average Medicare payment amount ($9.5k), and total discharges (93.9k).

State Payment Rates

State: Alaska1 / 49

Alaska Benchmarks

AK payer rates range from $19K (Anthem) up to $30K (Cigna), with BCBS at $13K mean sitting between those endpoints. Cigna’s mean payment in AK is a clear upward deviation from the national Cigna mean, while Anthem’s AK mean matches its national average. See the table and chart below for payer-level distributions and quartiles.

Key Insights for Alaska

Highest payer: Cigna (mean $30K); Lowest payer: Anthem (mean $19K).
Cigna in Alaska pays notably above the national mean for Cigna (~~$20K), while Anthem aligns with the national Anthem mean (~~$19K).

Clinical Trials

Acute respiratory support intervention trials: randomized studies comparing ventilatory strategies (e.g., high-flow nasal oxygen, noninvasive ventilation, and invasive mechanical ventilation protocols) or timing of intubation in patients admitted with acute respiratory failure and pulmonary edema. These trials enroll hospitalized adults with hypoxemic or hypercapnic respiratory failure, often stratified by cardiogenic versus noncardiogenic pulmonary edema, and evaluate short-term physiologic endpoints, duration of mechanical ventilation, and in-hospital complications. Findings directly inform bedside decisions in the critical care window, affecting LOS, resource utilization, and payer costs for this DRG.
Comparative effectiveness and management strategy studies for heart failure–related pulmonary edema: pragmatic trials and observational comparative-effectiveness research evaluating medical management approaches (diuretic strategies, vasoactive support algorithms, and fluid-management protocols) in patients whose respiratory failure is driven by acute decompensated heart failure. These studies focus on typical inpatient populations with cardiogenic pulmonary edema, assessing readmission rates, need for ICU-level care, and markers of decongestion; they help determine which inpatient pathways reduce recurrent hospitalization and downstream expenditures. Payers and hospital administrators use these results to guide care pathways, admission-level decisions, and care coordination that influence DRG costs.
Post-discharge outcomes and transitional care studies: prospective cohort studies and interventions testing transitional care bundles, early outpatient follow-up, remote monitoring, and rehabilitation for survivors of hospitalization for pulmonary edema and respiratory failure. These trials recruit patients discharged after an index hospitalization to evaluate 30- to 90-day readmissions, functional recovery, and health-related quality of life, as well as cost-effectiveness of post-discharge programs. This research is important for reducing readmissions and downstream costs associated with this DRG and for informing payer policies on post-acute services and bundled payment models.

Chronic Obstructive Pulmonary Disease with MCC: Inpatient Reimbursement Overview

188-PLEURAL-EFFUSION-WITHOUT-CC-MCC

Pleural Effusion without CC/MCC: Inpatient Reimbursement Overview

186-PLEURAL-EFFUSION-WITH-MCC

Pleural Effusion with MCC: Inpatient Reimbursement Overview

205-OTHER-RESPIRATORY-SYSTEM-DIAGNOSES-WITH-MCC

Other Respiratory System Diagnoses with MCC: Inpatient Reimbursement Overview

180-RESPIRATORY-NEOPLASMS-WITH-MCC

Respiratory Neoplasms with MCC: Inpatient Reimbursement Overview

201-PNEUMOTHORAX-WITHOUT-CC-MCC

Pneumothorax without CC/MCC: Inpatient Reimbursement Overview

194-SIMPLE-PNEUMONIA-AND-PLEURISY-WITH-CC

Simple Pneumonia and Pleurisy with CC: Inpatient Reimbursement Overview

175-PULMONARY-EMBOLISM-WITH-MCC-OR-ACUTE-COR-PULMONALE

Pulmonary Embolism with MCC or Acute Cor Pulmonale: Inpatient Reimbursement Overview

202-BRONCHITIS-AND-ASTHMA-WITH-CC-MCC

Bronchitis and Asthma with CC/MCC: Inpatient Reimbursement Overview

204-RESPIRATORY-SIGNS-AND-SYMPTOMS

Respiratory Signs and Symptoms: Inpatient Reimbursement Overview

Showing 1–10 of 40

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Average Total Payment	Average Submitted Charges	Average Medicare Payment	Total Discharges
$12K	$54K	$9.5K	94K